Optimizing Early-Stage NSCLC Management Through Multidisciplinary Strategies: ASCO 2025 - Episode 8
FDA Green-Lights Subcutaneous Nivolumab: What It Means for Early-Stage NSCLC Care
Panelists discuss how subcutaneous (SQ) nivolumab administration offers patient convenience and potential logistical advantages, particularly in the maintenance setting, though they acknowledge limited current adoption and need for more biological data on efficacy differences.
Video content above is prompted by the following:
With the FDA approval of SQ nivolumab, Wade Iams, MD, MSCI, and Josh Reuss, MD, reflect on the impact of this administration route in early-stage non–small cell lung cancer care. Although not yet widely adopted in their practices, they acknowledge its strong patient preference and potential to reduce clinic burden.
Although SQ immunotherapy may have limited impact during concurrent chemoimmunotherapy phases, it holds promise during the adjuvant setting, where shorter infusion times and ease of administration could significantly improve patient adherence and quality of life.
The panel calls for more data on the immunologic implications of SQ delivery, including its impact on efficacy and immune engagement. Still, they anticipate this modality will play an increasing role in future treatment designs and patient-centered care strategies.
Related Content:
